IFN-beta in rheumatoid arthritis

被引：45

作者：

Tak, PP ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Div Clin Immunol & Rheumatol, NL-1100 DE Amsterdam, Netherlands

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2004年 / 9卷

关键词：

rheumatoid arthritis; IFN-beta; synovial tissue; treatment; biologicals;

D O I：

10.2741/1475

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

IFN-beta is a cytokine with pleiotropic effects and is expressed in rheumatoid synovial tissue. Based on in vitro work and experiments in animal models of rheumatoid arthritis (RA), the effects are mainly anti-inflammatory. Of special interest is the ability of IFN-beta to reduce the secretion of TNF-alpha, IL-1 beta, and IL-6, which are all key players in the pathogenesis of RA. At the same time IFN-beta could enhance the production of anti-inflammatory mediators like IL-1 receptor antagonist ( IL-1Ra) and IL-10. Treatment of mice and monkeys with collagen-induced arthritis with daily IFN-beta injections resulted in clinical improvement, decreased synovial inflammation, and protection against joint destruction. Similar data were obtained after IFN-beta gene therapy. However, treatment of RA patients with IFN-beta has been unsuccessful so far, presumably due to pharmacokinetic issues. Novel approaches leading to constitutive IFN-beta production at the site of inflammation may be required to induce clinical efficacy in patients.

引用

页码：3242 / 3247

页数：6

共 57 条

[41] Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA [J].

Smeets, TJM ;

Kraan, MC ;

Galjaard, S ;

Youssef, PP ;

Smith, MD ;

Tak, PP .

ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (06) :561-565

[42]

Tak PP, 2000, ARTHRITIS RHEUM-US, V43, P2619, DOI 10.1002/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO

[43]

2-V

[44] Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity [J].

Tak, PP ;

Smeets, TJM ;

Daha, MR ;

Kluin, PM ;

Meijers, KAE ;

Brand, R ;

Meinders, AE ;

Breedveld, FC .

ARTHRITIS AND RHEUMATISM, 1997, 40 (02) :217-225

[45] The effects of interferon beta treatment on arthritis [J].

Tak, PP ;

't Hart, BA ;

Kraan, MC ;

Jonker, M ;

Smeets, TJM ;

Breedveld, FC .

RHEUMATOLOGY, 1999, 38 (04) :362-369

[46] RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β [J].

Takayanagi, H ;

Kim, S ;

Matsuo, K ;

Suzuki, H ;

Suzuki, T ;

Sato, K ;

Yokochi, T ;

Oda, H ;

Nakamura, K ;

Ida, N ;

Wagner, EF ;

Taniguchi, T .

NATURE, 2002, 416 (6882) :744-749

[47]

Triantaphyllopoulos KA, 1999, ARTHRITIS RHEUM, V42, P90, DOI 10.1002/1529-0131(199901)42:1<90::AID-ANR12>3.0.CO

[48]

2-A

[49] Treatment with recombinant interferon-β reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis [J].

van Holten, J ;

Reedquist, K ;

Sattonet-Roche, P ;

Smeets, TJM ;

Plater-Zyberk, C ;

Vervoordeldonk, MJ ;

Tak, PP .

ARTHRITIS RESEARCH & THERAPY, 2004, 6 (03) :R239-R249

[50] Interferon-β for treatment of rheumatoid arthritis? [J].

van Holten, J ;

Plater-Zyberk, C ;

Tak, PP .

ARTHRITIS RESEARCH, 2002, 4 (06) :346-352

← 1 2 3 4 5 6 →